II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Net Common Stock Issuance

Last Annual Value

65.84M

3-Year CAGR

%

5-Year CAGR

310%

10-Year CAGR

%

II

ImageneBio Inc Competitors Analysis of Net Common Stock Issuance

IMA · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
65.84M
21.3%-12.9%N/A 
225.00K
14.7%-49.4%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
75.50M
480.5%-20.5%N/A
12.23M
157.5%-22.6%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
65.58M
325.2%8.9%18.2%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
8.26M
N/A5.5%47.0%
48.08M
N/A16.6%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
4.44M
-33.4%-48.5%N/A
376.00K
-68.4%N/AN/A
75.21M
419.9%141.0%N/A
50.00M
N/A192.9%N/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69